Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFA14A
Source: 0001193125-25-086311
Chunk: 1

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFA14A
Chunk 1
---
 U.S. Securities and Exchange Commission (the “SEC”) in connection with the Company’s 2025 Annual Meeting of Stockholders (“Annual Meeting”), which is scheduled to take place on May 29, 2025. Stockholders of record as of April 4, 2025 will be entitled to vote at the Annual Meeting. Zevra’s Board of Directors strongly recommends that stockholders vote “FOR” the Company’s two highly-qualified directors up for re-electionon the WHITE proxy card – Wendy L. Dixon, Ph.D and Tamara A. Favorito, both of whom bring extensive public company board experience and life sciences management expertise to the Zevra Board. Both of these independent directors have contributed valuable perspectives that have helped accelerate the Company’s progress and execution of its strategic goals. In conjunction with the definitive proxy filing, Zevra is mailing a letter to stockholders detailing the decisive action the Company has taken over the past two years to transform Zevra into a stronger, growth-oriented commercial organization, which is poised to continue to drive significant stockholder value. The letter also addresses the attempt by an individual stockholder, Daniel J. Mangless, to replace two highly qualified directors with his nominees who could disrupt the clear progress underway and jeopardize Zevra’s ability to deliver long-term value for stockholders. As stockholders consider this important election, it is critical to remember that:

| • |     | The proactive and refreshed Zevra Board and management team have a proven track record of success, as                                                                                                                                      
 demonstrated by the continued progress and significant stockholder value creation during the last two years. Seven of eight directors have joined the Board since 2023 and Zevra’s refreshed management team has launched two rare disease 
 therapies, rapidly expanded the Company’s commercial capabilities, and positioned its pipeline for continued success.                                                                                                                      |

| • |     | The ongoing execution of Zevra’s strategy is designed to continue driving value over the coming 
 months and years.                                                                               |

| • |     | Zevra’s Board nominees are proven, experienced public company leaders and directors who have the                                                                                                                                           
 requisite company and industry expertise and fulfill the essential requirements for effective governance of a rapidly growing commercial-stage rare disease company. During their tenure, the Board’s nominees have initiated and overseen 
 substantial improvements to the Company.                                                                                                                                                                                                   |

| • |     | Despite owning just 2.8% of the Company and having already had three nominees elected to the Board in                                                                                                                                      
 2023, Mr